What does Oryzon Genomics, S.A.'s U.S. patent US12,564,559 B2 cover?

The patent covers methods of treating neoplastic diseases, including AML, using combinations comprising iadademstat and other therapeutic agents. The combinations notably include venetoclax, which the announcement describes as a backbone therapy in the current standard of care for first-line AML.

When is Oryzon Genomics, S.A.'s U.S. patent expected to expire?

Oryzon Genomics, S.A. said the patent is expected to expire in January 2039. This includes 681 days of patent term adjustment granted by the USPTO to compensate for delays during patent prosecution.

Could Oryzon Genomics, S.A.'s patent protection extend beyond January 2039?

The announcement says the expected January 2039 expiry does not include any potential patent term extension related to regulatory review. Such an extension could further extend the patent term, according to the company.

What is iadademstat being developed for by Oryzon Genomics, S.A.?

Iadademstat is Oryzon Genomics, S.A.'s potent and selective LSD1 inhibitor, and it is currently in clinical development in oncology and haematology. The company said it is being evaluated in seven ongoing oncology clinical trials.

How is Oryzon Genomics, S.A. evaluating iadademstat in first-line AML?

Oryzon Genomics, S.A. is evaluating iadademstat in the Phase Ib ALICE-2 study in first-line AML in combination with venetoclax and azacitidine. The announcement says the trial continues to enrol rapidly.

What preliminary ALICE-2 results did Oryzon Genomics, S.A. report?

Oryzon Genomics, S.A. said preliminary data presented at the American Society of Hematology (ASH) 2025 Annual Meeting showed a 100% overall response rate (ORR) and a 90% strict complete remission (CR) rate. These were preliminary results from the Phase Ib ALICE-2 study.

When will Oryzon Genomics, S.A. provide updated ALICE-2 data?

Oryzon Genomics, S.A. said updated data from approximately 15-16 patients, representing around 75% of the planned enrollment, are expected to be presented at the European Hematology Association Annual Congress in June 2026.

How does Oryzon Genomics, S.A. describe the importance of the U.S. patent grant?

Neus Virgili, Oryzon Genomics, S.A.'s Chief IP Officer, said the grant represents a significant addition to the company's growing intellectual property portfolio for iadademstat. She said the patent covers combinations with venetoclax and provides protection extending into 2039, which she described as strengthening the long-term value of the company's clinical programmes.

What other AML combination patents does Oryzon Genomics, S.A. hold?

Oryzon Genomics, S.A. said it also holds granted patents covering combinations of iadademstat with other AML therapies, including azacitidine and decitabine, in the United States and other countries.

What identifiers does Oryzon Genomics, S.A. provide in the announcement?

The announcement identifies Oryzon Genomics, S.A. by ISIN Code ES0167733015 and the symbol ORY. It does not state a trading venue in the provided content.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon reports U.S. patent grant for iadademstat and venetoclax combinations

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon reports U.S. patent grant for iadademstat and venetoclax combinations

Q: In which countries does Oryzon Genomics, S.A. have additional patent protection for iadademstat and venetoclax combinations?

Oryzon Genomics, S.A. said it has obtained patent protection for these combinations, or their use in treating cancer, in Australia, Brazil, Canada, Europe, India, Israel, Japan, Korea, Malaysia, Mexico, New Zealand and Russia. Additional patent applications are pending in other jurisdictions.

Published Monday, 23 March 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Regulatory approval
Published: Monday, 23 March 2026
Source announcement: oryzon.com

Key figures
Measure	Figure
Patent term	January 2039
Patent term adjustment (PTA)	681 days
Overall response rate (ORR)	100%
Strict complete remission (CR) rate	90%

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced that the USPTO granted a U.S. patent covering iadademstat combinations.

The patent, US12,564,559 B2, covers neoplastic disease treatments, including AML, using combinations with agents including venetoclax.
The company expects the patent to expire in January 2039, including 681 days of patent term adjustment.
Potential patent term extension related to regulatory review is not included and could further extend the patent term.
Preliminary data from ALICE-2 presented at ASH 2025 showed a 100% overall response rate and 90% strict complete remission rate.
The company expects updated data from approximately 15-16 patients, around 75% of planned enrollment, at EHA in June 2026.

Oryzon said it has patent protection for these combinations in Australia, Brazil, Canada, Europe, India, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, and Russia. Other applications remain pending, and granted patents cover azacitidine and decitabine combinations.

Investor FAQs

Oryzon Genomics, S.A. announced that the United States Patent and Trademark Office had granted U.S. patent US12,564,559 B2. The patent relates to therapeutic combinations of iadademstat, including combinations with venetoclax, for treating neoplastic diseases such as acute myeloid leukaemia (AML).

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON announces U.S. patent grant covering iadademstat combinations with venetoclax
Published: Monday, 23 March 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…